Hims & Hers $HIMS tumbles 15% on Q1 net loss and weak guidance
Original: Hims & Hers plummets 15% after first-quarter loss, weak earnings guidance View original →
Hims & Hers ($HIMS) fell roughly 15% on May 12, 2026 after the telehealth platform reported a first-quarter net loss and issued forward guidance below consensus expectations, according to CNBC.
Hims & Hers built significant revenue growth around compounded versions of semaglutide and tirzepatide — GLP-1 receptor agonists used for weight loss. Compound pharmacies were permitted to produce their own formulations while the branded drugs (Novo Nordisk's Ozempic/Wegovy and Eli Lilly's Mounjaro/Zepbound) were on the FDA's shortage list. Once the FDA removed semaglutide from that list, compound pharmacies lost their regulatory exemption, directly curtailing Hims & Hers' highest-margin product category.
The weak guidance signals that the transition away from compounded GLP-1 drugs is proving costly. Competing directly against branded manufacturers puts Hims at a structural disadvantage on pricing and distribution. Investors are focused less on the specific quarterly loss figure and more on the timeline and credibility of any alternative revenue pathway.
The company operates a multi-category telehealth platform covering hair loss, erectile dysfunction, women's health, and mental wellness. Growth in non-GLP-1 categories remains an open question as to whether it can absorb the compounded-drug headwind fast enough to satisfy near-term profitability expectations.
Key dates ahead: Q2 2026 earnings and any additional FDA guidance on compounded medications.
Not investment advice. Verify all figures with primary sources before acting.
Related Articles
Super Micro Computer shares jumped 18% after its fiscal Q3 2026 earnings showed revenue more than doubling year-on-year and guidance surpassing analyst estimates. The company also highlighted progress on U.S. manufacturing expansion, a key focus for hyperscaler customers seeking domestically produced hardware.
AMD shares surged 15% in after-hours trading on May 5, 2026, after Q1 results beat on both revenue and guidance. Data center growth — powered by MI-series GPUs and Epyc server CPUs — was the primary driver, reinforcing investor confidence that AI semiconductor demand remains robust.
Novo Nordisk raised its full-year 2026 guidance after Q1 sales hit $15.2 billion (+32% constant currency), driven by the oral Wegovy pill which now commands 65% of new GLP-1 prescriptions in the United States.
Comments (0)
No comments yet. Be the first to comment!